Lisanti Capital Growth LLC Invests $3.97 Million in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Lisanti Capital Growth LLC purchased a new stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 138,830 shares of the company's stock, valued at approximately $3,972,000. Lisanti Capital Growth LLC owned 0.30% of Pacira BioSciences as of its most recent filing with the SEC.

Several other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. raised its position in Pacira BioSciences by 0.3% in the first quarter. Vanguard Group Inc. now owns 5,113,384 shares of the company's stock valued at $149,413,000 after purchasing an additional 14,960 shares during the period. Frontier Capital Management Co. LLC raised its position in Pacira BioSciences by 15.8% in the fourth quarter. Frontier Capital Management Co. LLC now owns 2,084,542 shares of the company's stock valued at $70,332,000 after purchasing an additional 285,045 shares during the period. Dimensional Fund Advisors LP raised its position in Pacira BioSciences by 1.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,411,767 shares of the company's stock valued at $47,633,000 after purchasing an additional 17,949 shares during the period. Vestal Point Capital LP purchased a new stake in Pacira BioSciences in the fourth quarter valued at approximately $40,488,000. Finally, Clearbridge Investments LLC raised its position in Pacira BioSciences by 2.3% in the first quarter. Clearbridge Investments LLC now owns 1,172,150 shares of the company's stock valued at $34,250,000 after purchasing an additional 26,463 shares during the period. Hedge funds and other institutional investors own 99.73% of the company's stock.

Insider Buying and Selling

In related news, CEO Frank D. Lee purchased 8,264 shares of the stock in a transaction that occurred on Monday, August 12th. The shares were purchased at an average price of $12.10 per share, with a total value of $99,994.40. Following the completion of the acquisition, the chief executive officer now directly owns 107,784 shares in the company, valued at approximately $1,304,186.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CEO Frank D. Lee acquired 8,264 shares of Pacira BioSciences stock in a transaction that occurred on Monday, August 12th. The stock was purchased at an average price of $12.10 per share, for a total transaction of $99,994.40. Following the completion of the transaction, the chief executive officer now directly owns 107,784 shares in the company, valued at $1,304,186.40. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Lauren Riker sold 3,970 shares of the firm's stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $28.72, for a total transaction of $114,018.40. Following the completion of the sale, the senior vice president now owns 38,075 shares of the company's stock, valued at approximately $1,093,514. The disclosure for this sale can be found here. Over the last quarter, insiders have purchased 11,176 shares of company stock valued at $136,240 and have sold 22,095 shares valued at $621,118. Corporate insiders own 6.40% of the company's stock.

Pacira BioSciences Stock Performance

Shares of PCRX stock traded up $0.20 during mid-day trading on Friday, hitting $15.56. 702,297 shares of the stock were exchanged, compared to its average volume of 1,652,638. The stock's fifty day simple moving average is $19.50 and its two-hundred day simple moving average is $25.59. The stock has a market capitalization of $717.78 million, a price-to-earnings ratio of 10.88 and a beta of 0.88. Pacira BioSciences, Inc. has a 12-month low of $11.16 and a 12-month high of $36.55. The company has a debt-to-equity ratio of 0.67, a quick ratio of 5.70 and a current ratio of 6.82.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last issued its quarterly earnings data on Tuesday, July 30th. The company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.53 by $0.11. The company had revenue of $178.02 million for the quarter, compared to analyst estimates of $173.31 million. Pacira BioSciences had a return on equity of 13.22% and a net margin of 9.21%. On average, analysts forecast that Pacira BioSciences, Inc. will post 2.24 EPS for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Barclays lowered Pacira BioSciences from an "overweight" rating to an "equal weight" rating and cut their target price for the company from $38.00 to $25.00 in a research report on Wednesday, July 3rd. Truist Financial lowered Pacira BioSciences from a "buy" rating to a "sell" rating and cut their price objective for the stock from $30.00 to $8.00 in a research report on Tuesday, August 13th. StockNews.com lowered Pacira BioSciences from a "strong-buy" rating to a "buy" rating in a research report on Monday, August 12th. JPMorgan Chase & Co. reaffirmed an "underweight" rating and set a $10.00 price objective (down previously from $45.00) on shares of Pacira BioSciences in a research report on Monday, August 12th. Finally, Piper Sandler cut Pacira BioSciences from an "overweight" rating to a "neutral" rating and cut their price target for the company from $42.00 to $11.00 in a research note on Monday, August 12th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $24.78.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.